A Phase Ib Study of YY-20394 in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma

Relapsed or Refractory Peripheral T-Cell Lymphoma Clinical Trial

Official title:
A Single-Arm, Open-Label, Multi-Center, Phase Ib Study of YY-20394 in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma

Status Recruiting

Clinical Trial Summary

A single-arm, open, multicenter study to investigate the efficacy and safety of YY-20394, an oral small molecular inhibitor of PI3K-delta, in patients with relapsed or refractory peripheral T cell lymphoma.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Lymphoma
Lymphoma, T-Cell
Lymphoma, T-Cell, Peripheral
Relapsed or Refractory Peripheral T-Cell Lymphoma

Clinical Trial Details

NCT number	NCT04108325
Study type	Interventional
Source	Shanghai YingLi Pharmaceutical Co. Ltd.
Contact	Hanying Bao, PhD
Phone	86 21-5137069
Email	hybao@yl-pharma.com
Status	Recruiting
Phase	Phase 1
Start date	March 30, 2020
Completion date	December 2021

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03356678` - Pralatrexate for Relapsed or Refractory Peripheral T-cell Lymphoma	N/A
Completed	`NCT02464228` - Investigation of Tipifarnib in Treatment of Subjects With PTCL That Have Not Responded to Standard Therapy.	Phase 2
Recruiting	`NCT04329130` - Chidamide Combination With Lenalidomide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma	Phase 2
Recruiting	`NCT05833724` - Chidamide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (R/R PTCL)	Phase 2